Daniel A. Briere

LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept

Tamer Coşkun, Kyle W. Sloop, Corina Loghin et al. · Molecular Metabolism · 2018 · 766 citations · Full text

LY3437943, a novel triple glucagon, GIP, and GLP-1 receptor agonist for glycemic control and weight loss: From discovery to clinical proof of concept

Tamer Coşkun, Shweta Urva, William C. Roell et al. · Cell Metabolism · 2022 · 246 citations · Full text

GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice

Ricardo J. Samms, Michael E. Christe, Kyla Collins et al. · Journal of Clinical Investigation · 2021 · 204 citations · Full text

The novel dual glucose‐dependent insulinotropic polypeptide and glucagon‐like peptide‐1 ( <scp>GLP</scp> ‐1) receptor agonist tirzepatide transiently delays gastric emptying similarly to selective <scp>long‐acting GLP</scp> ‐1 receptor agonists

Shweta Urva, Tamer Coşkun, Corina Loghin et al. · Diabetes Obesity and Metabolism · 2020 · 116 citations · Full text

Substituted 3-Imidazo[1,2-<i>a</i>]pyridin-3-yl- 4-(1,2,3,4-tetrahydro-[1,4]diazepino- [6,7,1-<i>hi</i>]indol-7-yl)pyrrole-2,5-diones as Highly Selective and Potent Inhibitors of Glycogen Synthase Kinase-3

Thomas A. Engler, James R. Henry, Sushant Malhotra et al. · Journal of Medicinal Chemistry · 2004 · 100 citations · Full text

Insulin Receptor, Pharmaceutical Chemistry, Insulin Signaling +18